Drug InteractionPhase 1NCT06689527
Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics
A Phase 1 study testing Vamorolone and Midazolam in people with Drug Interaction, run by Santhera Pharmaceuticals at 1 site in Germany.
Trial summary
The purpose of this study was to investigate how vamorolone affects the CYP3A4 enzyme in humans by measuring the pharmacokinetics of midazolam and its metabolite, 1'-hydroxymidazolam, in healthy subjects. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Drug Interaction
- What is being tested?
- Vamorolone and Midazolam
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 1 siteGermany
- Study dates
- 13 Aug 2024to 16 Oct 2024
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age of 18 to 55 years inclusive, at the time of signing the informed consent.
- Subject is overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECG.
- Body weight ≥ 50 kg and a BMI ≥ 18 kg/m2 and ≤ 29.9 kg/m2 at screening.
- Male and female. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Male subjects:
- If the subject is a sexually active man and not surgically sterilized, he must be willing to:
Show all 27Show fewer
- Abstain from sexual intercourse or
- Use a condom plus another form of contraception, (e.g., spermicide, IUD, birth control pills taken by female partner) if engaging in sexual intercourse with a woman who could become pregnant.
- Use a condom during sexual intercourse with pregnant or lactating women.
- Must not father a child and must refrain from donating sperm from administration of the first dose and up to 3 months after the last dose of study treatment.
- Female subjects:
- All women (regardless of their status, i.e. WOCBP and WONCBP; for definitions see Section 10.4.1) must have a negative serum β-hCG pregnancy test prior to the initiation of the study treatments. FSH levels of suspected postmenopausal females must be \> 30 mIU/mL.
- Vamorolone has the potential to induce CYP3A4, which may result in a reduction in the effectiveness of contraceptives that are metabolized by CYP3A4 such as hormonal contraceptives when co-administered with vamorolone. Therefore, hormonal contraceptives by any route of administration are contraindicated.
- Women participating in the study must be either:
- WONCBP or
- WOCBP using, during the length of the study and for at least 3 months after the stop of the study treatments, 1 of the following contraceptive methods plus a condom:
- IUD during the study and up to 3 months after the last administration of the study treatments
- Any IUD with published data showing that the lowest expected failure rate is less than 1% per year (not all IUDs meet this criteria)
- Any other methods with published data showing that the lowest expected failure rate for birth control is less than 1% per year, or
- Abstinent from intercourse for 2 weeks before exposure to the study treatments, throughout the clinical trial until 3 months following discontinuation of the study treatments, or
- Have a male partner who is sterile prior to the woman's entry into the study and is the sole sexual partner for that woman during the study period.
- The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
- Subject is a non-smoker for at least 3 months prior exposure to the study treatments. Subject must also have abstained from use of other nicotine containing products (e.g., nicotine patch, chewing gum or e-cigarettes) for at least 3 months before exposure to the study treatments.
- Capable of giving signed informed consent as described in Section 10.1, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol prior to any clinical study specific procedure.
- Supine systolic blood pressure ≥ 90 mmHg and ≤ 140 mmHg; diastolic blood pressure ≥ 50 mmHg and ≤ 90 mmHg and pulse rate ≥ 45 bpm and ≤ 90 bpm, and tympanic body temperature ≥ 35.0 °C and ≤ 37.5 °C at screening.
- Subjects must be able to communicate well with the Investigator and comply with the protocol requirements, instructions, and protocol related restrictions (e.g. dietary, fluid and lifestyle restrictions from screening to study completion; Section 5.3).
- Subjects must be able to swallow the study treatments as per protocol.
Who cannot join
- A past medical history of clinically significant abnormalities or a history/family history of long QT interval syndrome, structural cardiac abnormalities (including but not limited to hypertrophic cardiomyopathy, valvulopathy, and congenital defects), or cardiogenic syncope.
- An abnormal ECG, defined as:
- PR \> 215 msec and \< 100 msec, QRS complex \> 120 msec; QTcF \> 450 msec by automated reading
- Any clinically significant ST/T wave abnormalities
- Any atrial or ventricular arrhythmias
- A past medical history of myocardial infarction, angina pectoris, atherosclerosis or other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension).
Show all 48Show fewer
- A past medical history of peptic ulcers, diverticulitis, and non-specific ulcerative colitis.
- History of complaints of frequent dizziness and /or vomiting spells or lightheadedness ("frequent" defined as incidence occurs more than once every week) or history of/or present sleep apnea.
- Any history or evidence of any clinically relevant, gastrointestinal, respiratory, hepatic, renal, endocrinologic, hematologic, immunologic, metabolic, genitourinary, pulmonary, neurologic, dermatologic, musculoskeletal, and/or other major disease or malignancy as determined by medical evaluation (including physical examination) capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study treatments; or interfering with the interpretation of data.
- Known Gilbert's syndrome.
- Any clinically relevant history of allergic conditions requiring hospitalization or prolonged systemic treatment (including drug allergies, allergic asthma, eczema, allergies requiring therapy with corticosteroids or anaphylactic reactions); but excluding untreated, asymptomatic, seasonal allergies at time of dosing or allergic contact sensitizations (e.g., nickel allergy).
- Known or suspected hypersensitivity or contraindications to vamorolone and/or midazolam or any components of the formulation used.
- Relevant current acute or chronic/recurrent viral, bacterial, fungal, or parasitic infections (e.g., pulmonary/upper respiratory, gastrointestinal, urinary, skin, or ENT infections) at screening or within 28 days prior to administration of the study treatments.
- Use of any concomitant medication or any drugs / medicines (including dietary supplements, natural and herbal remedies, and hormone replacement therapy) within 2 weeks or 5 times the half-life of the respective drug, whichever is longer, prior to the first administration of the study treatments.
- Occasional use of paracetamol up to 2 g/day or ibuprofen up to 1.2 g/day (medicinal products in their original packaging, approved and marketed in Germany) is permitted.
- Oral, injectable, and implantable contraceptives as outlined in Section 5.1 are permitted.
- Previous exposure to vamorolone.
- Any use of corticoids within 6 months prior to the first administration of the study treatments.
- Administration of live, attenuated, replication-competent vaccines within 6 weeks prior to the first administration of the study treatments until 2 weeks after the follow-up visit. Administration of vector-based or mRNA COVID-19 vaccines within 2 weeks prior to the first administration of the study treatments until 2 weeks after the follow-up visit.
- Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the first administration of the study treatments.
- Use of any investigational drug or participation in any clinical study within 30 days or 5 half-lives (whichever is longer) prior to the expected date of first administration of study treatments or planning to take other investigational drugs during the study.
- Positive results for HBsAg, anti-HCV, anti-HIV 1 and 2, and HIV 1-p24 antigen at screening.
- Positive screen for alcohol, drugs of abuse and cotinine at screening.
- Elevations in ALT \> 1.1 x ULN, AST \> 1.2 x ULN, serum bilirubin \> 1.2 x ULN, creatinine \> 1.1 x ULN and and HbA1c \> ULN at screening. A case-by-case decision for any abnormality must be discussed with the Sponsor before inclusion.
- TSH outside of normal ranges.
- eGFR based on the CKD-EPI (details for calculation see Section 10.2) of \< 90 mL/min at screening.
- Potassium or magnesium blood concentration below the lower limit of normal at screening.
- Subjects who are unwilling to adhere to contraceptive requirements.
- Higher than low-risk alcohol consumption i.e., consumption of an average weekly alcohol intake of \> 21 units/week for men and \> 14 units/week for women. 1 unit (12 g) corresponds to 0.3 L of beer/day or 0.12 L of wine/day or 1 glass (at 2 cL) of spirits/day.
- Excessive consumption of caffeine- or xanthine-containing food or beverages (\> 5 cups of coffee a day or equivalent) or inability to stop consuming from 48 hours prior to first planned administration of study treatments.
- Consumption of alcohol from 48 hours prior to admission.
- Consumption of high dose resveratrol-containing products or products with enzyme-inducing or enzyme-inhibiting properties (for details refer to Section 5.3.1) 14 days prior to first administration of study treatment.
- Regular consumption of poppy seed containing food prior to first administration of study treatment.
- Any use of drugs-of-abuse or alcohol abuse within 1 month prior to dosing.
- Subject with vegetarian, vegan, or restricted diet (e.g., gluten-free) or not willing or able to eat the complete standard meals.
- Female subject who has been pregnant within 6 months prior to screening or breastfeeding or lactating within 3 months prior to screening or plans to become pregnant during the clinical study period and for 3 months after final study treatment administration.
- Donation or loss of more than 400 mL of blood or received a transfusion of any blood or blood products within 30 days, or donated plasma within 30 days prior to first administration of study treatment.
- Strenuous physical activity within 72 h to admission.
- Employee of the Sponsor, the Nuvisan Group, or other Contract Research Organization involved in the clinical study.
- Legal incapacity or limited legal capacity, or incarceration and vulnerable subjects.
- Inability to understand or communicate reliably with the Investigator or considered by the Investigator to be unable to or unlikely to co-operate with the protocol requirements, instructions, and study-related restrictions.
- History of non-compliance to medical regimens and subjects who are considered potentially unreliable (e.g., refuse to comply with study regulations).
- Any other conditions or factors which in the opinion of the Investigator may interfere with study conduct.
- Changes in medical conditions compared to screening, as judged by the Investigator.
- Body weight \< 50 kg.
- Changes in prior/concomitant therapy compared to screening, as judged by the Investigator.
- Positive screen for alcohol, drugs of abuse and cotinine test upon admission.
- Changes in other exclusion criteria compared to screening, as judged by the Investigator.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open-label, Single-arm Study to Evaluate the CYP3A4 Induction Potential of Vamorolone on the Pharmacokinetics of Midazolam (a Sensitive CYP3A4 Probe) in Healthy Subjects.
The purpose of this study was to investigate how vamorolone affects the CYP3A4 enzyme in humans by measuring the pharmacokinetics of midazolam and its metabolite, 1'-hydroxymidazolam, in healthy subjects. The pharmacokinetics of midazolam were measured on Day 1 and then on Day 14 to investigate the potential interaction between the two compounds.
The safety and the tolerability was also investigated.
Read the detailed description
This was a non-randomized, single-center, open-label, single-sequence, single-arm Phase I study.
- Day 1: Participants received a single dose of 2.5 mg midazolam in fasted state in the morning.
- Day 2: Wash-out period.
- Days 3 to 13: Participants received daily doses of 6 mg/kg vamorolone in the morning within 30 minutes after start of a standard breakfast.
- Day 14: Participants received single doses of 2.5 mg midazolam and 6 mg/kg vamorolone in fasted state in the morning.
- Safety and tolerability parameters were collected during the entire study phase from screening to follow-up.
- Blood samples for PK assessment of midazolam and 1'-hydroxymidazolam were collected from predose through 10 hours following the midazolam doses on Days 1 and 14.
- Blood samples for PK assessment of vamorolone were collected throughout the vamorolone dosing period.
- Blood and urine biomarkers samples for CYP3A4 induction assessment were collected throughout the treatment period.
- On Day 28, a follow-up safety phone call was done
- Conditions
- Drug Interaction
- Being tested
- Vamorolone, Midazolam
- Keywords
- Drug-Drug-Interaction Study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VamoroloneDrug
Also called Test Drug
Days 3 to 14: 6 mg/kg vamorolone once daily.
MidazolamDrug
Also called Reference Drug
Day 1 and 14: Single oral doses of 2.5 mg midazolam
| Study group | Role | What they receive |
|---|---|---|
| Midazolam/Vamorolone | Experimental | Single oral dose midazolam 2.5mg on day 1 Single oral suspension vamorolone 6mg/kg on day 3 to day 13 Single oral dose midazolam 2.5mg + Single oral suspension vamorolone 6mg/kg on day 14 Receives: Drug: Vamorolone; Drug: Midazolam |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUC0-tlast of Midazolam
Area under the plasma concentration-time curve from 0 to the time of the last observed concentration (h*pg/mL) on day 1 and day 14. The timepoints at which the data were collected to create the curve are as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours postdose.
Measured: Day 1 and Day 14
AUC0-inf of Midazolam
Area under the plasma concentration-time curve from zero to infinite time on day 1 and day 14. The timepoints at which the data were collected to create the curve are as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours postdose and extrapolation to infinity.
Measured: Day 1 and Day 14
Cmax of Midazolam
maximum measured concentration of midazolam after administration of midazolam until the last collection time, i.e., 10 hours after dosing on day 1 and day 14
Measured: Day 1 and Day 14
AUC0-tlast of 1'-Hydroxymidazolam
Area under the plasma concentration-time curve from 0 to the time of the last observed concentration (h*pg/mL) on day 1 and day 14. The timepoints at which the data were collected to create the curve are as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours postdose.
Measured: Day 1 and Day 14
AUC-inf of 1'-Hydroxymidazolam
Area under the plasma concentration-time curve from 0 to the infinite time (h*pg/mL) on day 1 and Day 14. The timepoints at which the data were collected to create the curve are as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours postdose and extrapolation to infinity.
Measured: Day 1 and Day 14
Cmax of 1'-Hydroxymidazolam
maximum measured concentration of 1'-Hydroxymidazolam after administration of midazolam until the last collection time, i.e., 10 hours after dosing
Measured: Day 1 and Day 14
Secondary outcomes (9)
Tmax of Midazolam
Time to reach observed maximal concentration of midazolam after administration of midazolam until the last collection time, i.e., 10 hours after administration on day 1 and day 14
Measured: Day 1 and Day 14
CL/F of Midazolam
The apparent clearance measures how quickly a drug leaves the body, considering how much reaches it after being taken orally. It was calculated using the formula: Dose/AUCinf on day 1 and day 14. The timepoints used were as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 hours on day 1 and day 14
Measured: Day 1 and Day 14
Vz/F of Midazolam
Vz/F is the ratio of the volume of distribution of a drug to its bioavailability. It describes how widely the drug is distributed in the body after oral administration. It was calculated based on the terminal phase (ℷz)using the formula: Dose /ℷz.AUCinf on day 1 and day 14. The timepoints were as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 hours.
Measured: Day 1 and Day 14
t1/2 of Midazolam
Elimination half-life is the amount of time it takes for the concentration of the drug (midazolam) in the body to decrease by half after administration on day 1 and day 14. The collection times were predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 hours.
Measured: Day 1 and Day 14
Tmax of 1'-Hydroxymidazolam
Time to reach observed maximal concentration of 1'-Hydroxymidazolam after administration of midazolam until the last collection time, i.e., 10 hours after dosing on day 1 and day 14
Measured: Day 1 and Day 14
t1/2 of 1'-Hydroxymidazolam
Elimination half-life is the amount of time it takes for the concentration of the drug (1'-Hydroxymidazolam) in the body to decrease by half on day 1 and day 14. The collection times were predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 hours.
Measured: Day 1 and Day 14
Predose Concentration (Ctrough) of Vamorolone
Concentration measurements taken just before the first administration of vamorolone on day 3, and at the end of each vamorolone dosing interval before the next dose on days 4, 7, 11, 13, and 14.
Measured: Day 3, Day 4, Day 7, Day 11, Day 13, Day 14
Urinary 6β-hydroxycortisol to Cortisol Ratio
Urinary 6β-hydroxycortisol to cortisol ratio is used as in vivo biomarkers for CYP3A4 activity. The impact of vamorlone on adrenal suppression could result in alterations in urinary cortisol and 6-β-hydroxycortisol levels.. Thus, the 6-β-hydroxycortisol to cortisol ratio is an unreliable measure of vamorolone's CYP3A4 induction potential.
Measured: Day 1, Day 3, Day 4, Day 7, Day 11, Day 14, Day 15
Plasma 4β-hydroxycholesterol Level
The plasma concentration of 4-β-hydroxycholesterol is used as an in vivo marker to assess CYP3A4 induction activity
Measured: Day 1, Day 3, Day 4, Day 7, Day 11, Day 14, Day 15
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2024
- Study start13 Aug 2024
- Primary completion24 Sep 2024
- Study completion16 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Drug InteractionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A single-center, open-label, single-arm, fixed-sequence, design. Healthy male and female subjects (18 to 55 years, inclusive) are eligible.
- Masking
- None (open label)
- Enrolment
- 18 participants (actual)
Sponsor and investigators
- Lead sponsor
- Santhera Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Michael Lissy, MD, Principal investigator, Nuvisan GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06689527
- Sponsor's protocol ID
- SNT-I-VAM-025
- Other IDs
- 2024-513845-36-00
- Status last verified
- Dec 2025
- First submitted
- 5 Sep 2024
- Last updated
- 15 Dec 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label, Single-arm Study to Evaluate the CYP3A4 Induction Potential of Vamorolone on the Pharmacokinetics of Midazolam (a Sensitive CYP3A4 Probe) in Healthy Subjects.
- ClinicalTrials.gov ID
- NCT06689527
- Acronym / sponsor ID
- SNT-I-VAM-025
- Conditions
- Drug Interaction
- Keywords
- Drug-Drug-Interaction Study
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 18 participants (actual)
- Lead sponsor
- Santhera PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 13 Aug 2024 (actual)
- Primary completion
- 24 Sep 2024 (actual)
- Study completion
- 16 Oct 2024 (actual)
- First posted
- 14 Nov 2024 (actual)
- Results
- Posted 15 Dec 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to investigate how vamorolone affects the CYP3A4 enzyme in humans by measuring the pharmacokinetics of midazolam and its metabolite, 1'-hydroxymidazolam, in healthy subjects. The pharmacokinetics of midazolam were measured on Day 1 and then on Day 14 to investigate the potential interaction between the two compounds.
The safety and the tolerability was also investigated.
Detailed description
This was a non-randomized, single-center, open-label, single-sequence, single-arm Phase I study.
- Day 1: Participants received a single dose of 2.5 mg midazolam in fasted state in the morning.
- Day 2: Wash-out period.
- Days 3 to 13: Participants received daily doses of 6 mg/kg vamorolone in the morning within 30 minutes after start of a standard breakfast.
- Day 14: Participants received single doses of 2.5 mg midazolam and 6 mg/kg vamorolone in fasted state in the morning.
- Safety and tolerability parameters were collected during the entire study phase from screening to follow-up.
- Blood samples for PK assessment of midazolam and 1'-hydroxymidazolam were collected from predose through 10 hours following the midazolam doses on Days 1 and 14.
- Blood samples for PK assessment of vamorolone were collected throughout the vamorolone dosing period.
- Blood and urine biomarkers samples for CYP3A4 induction assessment were collected throughout the treatment period.
- On Day 28, a follow-up safety phone call was done
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A single-center, open-label, single-arm, fixed-sequence, design. Healthy male and female subjects (18 to 55 years, inclusive) are eligible.
| Arm | Type | Receives |
|---|---|---|
| Midazolam/Vamorolone | Experimental | Drug: Vamorolone, Drug: MidazolamSingle oral dose midazolam 2.5mg on day 1 Single oral suspension vamorolone 6mg/kg on day 3 to day 13 Single oral dose midazolam 2.5mg + Single oral suspension vamorolone 6mg/kg on day 14 |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (27 listed)
- Age of 18 to 55 years inclusive, at the time of signing the informed consent.
- Subject is overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECG.
- Body weight ≥ 50 kg and a BMI ≥ 18 kg/m2 and ≤ 29.9 kg/m2 at screening.
- Male and female. Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- All women (regardless of their status, i.e. WOCBP and WONCBP; for definitions see Section 10.4.1) must have a negative serum β-hCG pregnancy test prior to the initiation of the study treatments. FSH levels of suspected postmenopausal females must be \> 30 mIU/mL.
Key exclusion criteria (48 listed)
- A past medical history of clinically significant abnormalities or a history/family history of long QT interval syndrome, structural cardiac abnormalities (including but not limited to hypertrophic cardiomyopathy, valvulopathy, and congenital defects), or cardiogenic syncope.
- An abnormal ECG, defined as:
- A past medical history of myocardial infarction, angina pectoris, atherosclerosis or other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension).
- A past medical history of peptic ulcers, diverticulitis, and non-specific ulcerative colitis.
- History of complaints of frequent dizziness and /or vomiting spells or lightheadedness ("frequent" defined as incidence occurs more than once every week) or history of/or present sleep apnea.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VamoroloneAlso: Test DrugDays 3 to 14: 6 mg/kg vamorolone once daily. | Drug | Midazolam/Vamorolone |
| MidazolamAlso: Reference DrugDay 1 and 14: Single oral doses of 2.5 mg midazolam | Drug | Midazolam/Vamorolone |
Primary outcome
AUC0-tlast of Midazolam
Time frame: Day 1 and Day 14
Area under the plasma concentration-time curve from 0 to the time of the last observed concentration (h*pg/mL) on day 1 and day 14. The timepoints at which the data were collected to create the curve are as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours postdose.
AUC0-inf of Midazolam
Time frame: Day 1 and Day 14
Area under the plasma concentration-time curve from zero to infinite time on day 1 and day 14. The timepoints at which the data were collected to create the curve are as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours postdose and extrapolation to infinity.
Cmax of Midazolam
Time frame: Day 1 and Day 14
maximum measured concentration of midazolam after administration of midazolam until the last collection time, i.e., 10 hours after dosing on day 1 and day 14
AUC0-tlast of 1'-Hydroxymidazolam
Time frame: Day 1 and Day 14
Area under the plasma concentration-time curve from 0 to the time of the last observed concentration (h*pg/mL) on day 1 and day 14. The timepoints at which the data were collected to create the curve are as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours postdose.
AUC-inf of 1'-Hydroxymidazolam
Time frame: Day 1 and Day 14
Area under the plasma concentration-time curve from 0 to the infinite time (h*pg/mL) on day 1 and Day 14. The timepoints at which the data were collected to create the curve are as follows: predose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hours postdose and extrapolation to infinity.
Cmax of 1'-Hydroxymidazolam
Time frame: Day 1 and Day 14
maximum measured concentration of 1'-Hydroxymidazolam after administration of midazolam until the last collection time, i.e., 10 hours after dosing
9 secondary outcomes
Tmax of Midazolam
Time frame: Day 1 and Day 14
CL/F of Midazolam
Time frame: Day 1 and Day 14
Vz/F of Midazolam
Time frame: Day 1 and Day 14
t1/2 of Midazolam
Time frame: Day 1 and Day 14
Tmax of 1'-Hydroxymidazolam
Time frame: Day 1 and Day 14
t1/2 of 1'-Hydroxymidazolam
Time frame: Day 1 and Day 14
Predose Concentration (Ctrough) of Vamorolone
Time frame: Day 3, Day 4, Day 7, Day 11, Day 13, Day 14
Urinary 6β-hydroxycortisol to Cortisol Ratio
Time frame: Day 1, Day 3, Day 4, Day 7, Day 11, Day 14, Day 15
Plasma 4β-hydroxycholesterol Level
Time frame: Day 1, Day 3, Day 4, Day 7, Day 11, Day 14, Day 15
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Drug Interaction
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Modeling Host-Pathogen Interaction Using Lymphoid Organoids
Staphylococcal Infections
RecruitingPhase 1
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
Healthy Volunteer, Pharmacokinetics
RecruitingObservational study
Pediatric Research in the Outpatient Setting CoHort
Parental Stress, Communication Disorder, Childhood
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Lissy, MD principal investigator
Nuvisan GmbH
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Vamorolone and Midazolam in people with Drug Interaction, run by Santhera Pharmaceuticals at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 27 inclusion and 48 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 Dec 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUC0-tlast of Midazolam (time frame: Day 1 and Day 14). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2025.